Vistusertib

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerBladder CancerPhase IIPediatric CancerBRCA1 Mutation Carrier

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Carboplatin Plus Paclitaxel

Bayer

Phase 3

22

HB1801

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

23

Consolidative Therapy

SSun Yat-sen University

Phase 3

24

Vistusertib

AstraZeneca

Phase 2

15

Remeron

OOrganon and Co

Preclinical

16

Treatment

GSK

Preclinical

17

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

18

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Small Cell Lung Cancer2 trials

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT03366103·15 enrolled

Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification

Terminated·SSamsung Medical Center·Phase 2·NCT03106155·4 enrolled

Chemotherapy2 trials

Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy

Withdrawn·SSamsung Medical Center·Phase 2·NCT03166904

Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy

Withdrawn·SSamsung Medical Center·Phase 2·NCT03166176

Relapsed/Refractory B-cell Malignancies1 trial

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Terminated·AAcerta Pharma BV·Phase 1/2·NCT03205046·25 enrolled

Phase II1 trial

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Active, not recruiting·AstraZeneca·Phase 2·NCT03334617·528 enrolled

Non-Small Cell Lung Cancer1 trial

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Active, not recruiting·UUniversity of Birmingham·Phase 2·NCT02664935·423 enrolled

3 more indications

Bladder Cancer1 trial

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Active, not recruiting·AstraZeneca·Phase 1·NCT02546661·117 enrolled

BRCA1 Mutation Carrier1 trial

A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02208375·159 enrolled

Pediatric Cancer1 trial

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Preclinical·NCT02813135·472 enrolled

Details

Drug Info

Related News